Skip to content
At the Pantheon Awards 2022 event on Thursday, California Life Sciences (CLS) honored three Biotechnology Innovation Organization (BIO) leaders and member companies. CLS is a member of the Council of State Bioscience Associations (CSBA), a confederation of state-based, non-profit trade organizations representing America’s life sciences industry.
Leading figures from the field are joined together for an evening of celebration at the annual Pantheon event, which recognizes the accomplishments of California’s life sciences.
BIO Chair Paul Hastings, CEO of Nkarta Therapeutics, and BIO Vice-Chair Dr. Ted Love, CEO of Global Blood Therapeutics, were jointly awarded the Pantheon Award for Leadership, as CLS posted on Twitter last night.
JUST ANNOUNCED: There are TWO incredible winners of the #Pantheon2022 Leadership Award: @phastings14 of @nkartatx and Ted Love of @GBT_news! pic.twitter.com/ACNuXb8Jp5
— California Life Sciences (CLS) (@CALifeSciences) November 4, 2022
The CLS Pantheon Leadership Award is presented to an individual or people who use cutting-edge business models and innovative practices in support of their team and the life sciences.
The award winners are “recognized for overall achievement in and contribution to the California life sciences community, ability to create and execute on a vision, mentorship of future leaders, notable track record of value-creation, and support of initiatives that impact the patients served.”
“Nkarta CEO and BIO Chair Paul Hastings is a patient turned innovator, channeling unique perspectives to reset biopharma’s relationship with patients and champion biotechnology innovation. Hastings chairs the Youth Rally advocacy organization and helped launch the Biotech Social Contract, the BIO Patient Advocacy Summit, BIO Equality, and OUTbio Bay Area. At Nkarta, he is spearheading developing NK cell therapies for cancer,” California Life Sciences says.
Dr. Love joined Global Blood Therapeutics (GBT) in 2014 to address the long-standing needs of underserved patient communities, starting with sickle cell disease. Before that, he was at the forefront of R&D and technical operations at Onyx Pharmaceuticals. He also served as CEO of Nuvelo and held senior roles at Theravance and Genentech, as well.
Dr. Love is now serving on the boards of SeaGen and Royalty Pharma; he is the vice chair of board of BIO, and a founding board member of Life Science Cares Bay.
GBT was recently acquired by Pfizer, boosting Pfizer’s sickle cell pipeline, Bio.News previously reported.
Twist Bioscience gets recognition for its synthetic DNA
At the same event, BIO member Twist Bioscience, which offers high-quality synthetic DNA, was awarded the Pantheon Synthetic and Ag Bio Award.
CONGRATULATIONS to @TwistBioscience for winning the #Pantheon2022 Synthetic & Ag Bio Award! pic.twitter.com/vnzMdITfT8
— California Life Sciences (CLS) (@CALifeSciences) November 4, 2022
In its 19-year existence, the CLS has recognized distinction in a number of fields, including leadership, education, business deal-making, product creation, and other endeavors vital to the growth of the world’s life sciences ecosystem.
BIO sponsored the 2022 Pantheon Awards.
